Updated Results from the TOPAZ-1 Study of Durvalumab plus GemCis in Patients with Advanced BTC

2022 Year in Review: Cholangiocarcinoma — January 4, 2023

The phase 3 TOPAZ-1 study was a placebo-controlled study designed to evaluate durvalumab (D) plus gemcitabine/cisplatin (GemCis) for the treatment of advanced biliary tract cancer. Interim results suggested that D plus GemCis significantly improved overall survival (OS) in these patients compared with placebo (PBO) plus GemCis.1 The data reported here were presented at the 2022 ASCO GI Cancers Symposium and provide updated OS and safety analyses for the TOPAZ-1 study after an additional 6 months of follow-up.

Patients randomly assigned (1:1) in TOPAZ-1 were previously untreated for unresectable locally advanced, recurrent, or metastatic BTC. They received either D (1500 mg every 3 weeks) or PBO, as well as GemCis (1000 mg/m2 and 25 mg/m2, respectively) on days 1 and 8 every 3 weeks for a maximum of 8 cycles, followed by D (1500 mg every 4 weeks) or PBO monotherapy until disease progression or unacceptable toxicity. OS was evaluated for the entire patient population as well as several subgroups.

Median follow-up times were 23.4 months (95% confidence interval [CI], 20.6-25.2) for the D plus GemCis arm (n = 341) and 22.4 months (95% CI, 21.4-23.8) for the PBO plus GemCis arm. For the D plus GemCis group, median OS was 12.9 months (95% CI, 11.6-14.1), and it was 11.3 months (95% CI, 10.1-12.5) for the PBO plus GemCis group (hazard ratio [HR], 0.76; 95% CI, 0.64-0.91). When OS HRs were evaluated for prespecified subgroups, including disease status, primary tumor location, and PD-L1, all favored D plus GemCis. For disease status, OS HRs were 0.79 (95% CI, 0.65-0.95) and 0.76 (95% CI, 0.49-1.20) for initially resectable and recurrent disease, respectively. For primary tumor location, the OS HR for intrahepatic cholangiocarcinoma (CCA) was 0.78 (95% CI, 0.62-0.99), the OS HR for extrahepatic CCA was 0.61 (95% CI, 0.41-0.91), and the OS HR for gallbladder cancer was 0.90 (95% CI, 0.64-1.25). With regard to PD-L1, OS HRs were 0.75 (95% CI, 0.60-0.93) and 0.79 (95% CI, 0.58-1.09) for tumor area positivity (TAP) ≥1% and TAP <1%, respectively. OS rates for D plus GemCis versus PBO plus GemCis were as follows: 54.3% versus 47.1% at 12 months, 34.8% versus 24.1% at 18 months, and 23.6% versus 11.5% at 24 months. In addition, a higher proportion of patients responded to D plus GemCis versus PBO plus GemCis (26.7% vs 18.7%).

In the D plus GemCis arm, 60.9% of patients experienced grade 3/4 treatment-related adverse events (TRAEs), and TRAEs led to discontinuation of the study medication in 8.9% of these patients. In the PBO plus GemCis arm, 63.5% of patients experienced grade 3/4 TRAEs, and TRAEs led to discontinuation of the study medication in 11.4% of these patients. Adverse events in this follow-up were similar between treatment arms and consistent with the safety analysis previously reported.

Because of the clinically meaningful benefit and manageable safety profile of D plus GemCis versus PBO plus GemCis, it may be considered a new first-line standard of care for patients with advanced BTC.

Reference

  1. Oh DY, He AR, Qin S, et al. A phase 3, randomized, double blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients with advanced biliary tract cancer (BTC): TOPAZ-1. J Clin Oncol. 2022;40(suppl 4):378-378.

Sources: Oh D, He AR, Qin S, et al. Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC). Ann Oncol. 2022;33(suppl 7):S19-S26.

Oh DY, He, AR, Qin S. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2022. Abstract 378.

Related Items

KEYNOTE-966: Pembrolizumab Combined With GemCis Versus GemCis Alone in Patients With BTC
2023 Year in Review: Cholangiocarcinoma
In the KEYNOTE-966 study, pembrolizumab was added to gemcitabine/cisplatin to assess outcomes in patients with advanced biliary tract cancer.
Post-hoc Analysis of the ABC-01, -02, and -03 Trials in Patients With Advanced eCCA
2023 Year in Review: Cholangiocarcinoma
This post-hoc analysis of the ABC-01, -02, and -03 clinical trials provides reference survival data for patients with advanced extrahepatic cholangiocarcinoma treated with first-line gemcitabine/cisplatin chemotherapy.
Efficacy and Safety of Tinengotinib in Patients With Advanced Refractory/Relapsed CCA Who Previously Received an FGFR Inhibitor
2023 Year in Review: Cholangiocarcinoma
Investigators pooled data from 3 trials to evaluate tinengotinib in patients with advanced, refractory/relapsed cholangiocarcinoma who previously received an FGFR inhibitor.
KLF5 Inhibition Reduces Tumor Growth and Sensitizes to Chemotherapy-Induced Cell Death in Experimental Models of CCA
2023 Year in Review: Cholangiocarcinoma
Researchers evaluated KLF5 expression and its inhibition in cholangiocarcinoma using clustered regularly interspaced short palindromic repeats technology.
Phase 2 Trial of SHR-1316 Plus IBI310 in Patients With Advanced iCCA After Inadequate Response to First-Line Therapy
2023 Year in Review: Cholangiocarcinoma
In this ongoing phase 2 study, the efficacy of SHR-1316 plus IBI310 is being evaluated in patients with advanced intrahepatic cholangiocarcinoma after inadequate response to first-line therapy.
Examination of Patients With CCA Treated With Novel Targeted Therapies After Extended Molecular Profiling on Liquid Biopsies
2023 Year in Review: Cholangiocarcinoma
Dr Mahmood presented results from the largest multi-institutional review of efficacy outcomes following targeted agents in patients with cholangiocarcinoma.
Phase 2 Component of the BEER-BTC Study: Comparing Bevacizumab Plus Erlotinib Maintenance Versus Observation in Patients With Advanced BTC
2023 Year in Review: Cholangiocarcinoma
In the phase 2 component of the phase 2/3 BEER-BTC study, bevacizumab plus erlotinib improved outcomes in patients with advanced biliary tract cancers.
The DEBATE Trial: Neoadjuvant Durvalumab Plus GemCis Versus GemCis Alone for Patients With Localized BTC
2023 Year in Review: Cholangiocarcinoma
Researchers investigated the efficacy and safety of neoadjuvant durvalumab plus gemcitabine/cisplatin (GemCis) versus GemCis alone in patients with biliary tract cancer.
The Phase 2 ADJUBIL Study of Durvalumab Plus Tremelimumab With or Without Capecitabine in BTC
2023 Year in Review: Cholangiocarcinoma
In the ongoing phase 2 ADJUBIL study, the clinical activity of immunotherapies durvalumab and tremelimumab with or without capecitabine is being assessed in patients with resectable biliary tract cancer in the adjuvant setting.
Tucatinib and Trastuzumab in Patients With Previously Treated HER2-Positive Metastatic BTC: The SGNTUC-019 Study
2023 Year in Review: Cholangiocarcinoma
This phase 2 basket study investigated the combination of tucatinib and trastuzumab as second-line treatment for patients with HER2-positive biliary tract cancer.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: